
Saturday, January 21, 2023 8:01:36 PM
Artizen's spin-off PR said the "newly public Artizen"...will be able to "raise financing" and finalize "acquisition opportunities".
IMO, this is the alternative path to liquidity KK referred to. A few months ago, he said GERS shareholders will be issued shares in a "newly-public entity"...that would have the ability to conduct "new financing...and...acquisitions" That the transaction would involve his pre-existing equity interest in Artizen.
KK's pre-existing interest in Artizen is 161,500 (19%) of series K preferred shares.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=168435501
The Company accordingly shifted its focus to a potential alternative transaction which would provide each of our shareholders with new shares in a newly-public entity in addition to their current holdings in the Company. If that transaction is successful, and no assurances can be given in that regard, then the newly-public entity would be free of the constraints described in the first paragraph above, and it would therefore have the ability to conduct new financing, reverse mergers, acquisitions, and other transactions.
- The alternative path to liquidity will likely take the form of a distribution or other transaction under which the Company’s common shareholders of record are issued shares in another publicly-traded company at a premium to the Company’s current market price, subject to fulfillment of the required conditions and the blessings of counsel for all applicable parties. That transaction is likely to involve a pre-existing equity interest in Artizen Corporation.
Good Luck To All!$!$
Glidelogic Corp. Announces Release of First AI-Generated Novel "The Thirteenth Proposal" • GDLG • Jul 11, 2025 12:20 PM
Fifty1 AI Labs' REVIVE Clinical Trial Redefines Long COVID Treatment, Pioneering AI-Driven Therapies and Propelling Fifty 1 Labs, Inc. Toward $50M Valuation and Global Biotech Leadership • FITY • Jul 10, 2025 8:30 AM
Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB™, its New Sublingual Pre-Workout Supplement • ASBP • Jul 9, 2025 9:15 AM
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers • IBRX • Jul 9, 2025 9:00 AM
Fifty 1 Labs, Inc. Announces Bold Expansion Plan Powered by Nobel Prize Laureate Management Team, Cutting-Edge AI Healthcare Innovation and $350K Leadership Investment • FITY • Jul 8, 2025 8:30 AM
Avant Technologies and Partner, Ainnova, Launch Transformative Preventative Care Model for Chronic Patients Across Latin America • AVAI • Jul 8, 2025 8:00 AM